ST 016907

CAS No. 329071-59-2

ST 016907( ST016907 )

Catalog No. M14083 CAS No. 329071-59-2

A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    ST 016907
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo.
  • Description
    A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ST016907
  • Pathway
    GPCR/G Protein
  • Target
    Chemokine Receptor
  • Recptor
    Chemokine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    329071-59-2
  • Formula Weight
    636.555
  • Molecular Formula
    C24H15Cl2N5O4S4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N-(2,6-dichlorophenyl)-2-((6-(2-((6-nitrobenzo[d]thiazol-2-yl)thio)acetamido)benzo[d]thiazol-2-yl)thio)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bayry J, et al. Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10221-6.
molnova catalog
related products
  • Elubrixin tosylate

    Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.

  • IT1t dihydrochloride

    A highly potent, selective, orally bioavailable CXCR4 inhibitor with binding IC50 of 8 nM for hCXCR4, IC50 of 1.1 nM in Ca2+-mobilization assays.

  • AZD 1678

    AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4.